Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$TNDM Q4 '24 Earnings Results & Recap
Tandem Diabetes' Q4'24 results showed EPS of $0.01 (beating expectations of -$0.21), and revenue of $252.45M (beating expectations of $250.58M). The company anticipates 10-11% worldwide sales growth in 2025, with key drivers including the new Control IQ Plus algorithm and expansion into the pharmacy market, though potential headwinds remain due to the transition to direct sales in Europe.3
